Katherine Bonter

Katherine Bonter has over two decades of work experience in the field of intellectual property (IP) and commercialization strategy, particularly in the biopharmaceutical industry. Katherine is currently the Executive Director IP and Founder at Congruence Therapeutics, a position they started in January 2022. Prior to that, they worked at Ipsen as the Director of Clinical Sciences from January 2019 to June 2021, where they provided scientific support for rare disease clinical development efforts and played a key role in evaluating and acquiring new assets. Before Ipsen, Katherine held the position of Director of Intellectual Property at Clementia Pharmaceuticals Inc. from January 2017 to January 2019, where they led the development and prosecution of the company's IP portfolio in the field of rare diseases.

Additionally, Katherine has worked as an independent consultant, providing IP and competitive intelligence analysis for cell therapy development projects, supporting the strategy development of non-profit organizations promoting personalized medicine, and managing the IP portfolio for a small bio-pharma firm. Katherine was also involved in academic research projects focused on immunotherapy development and IP strategy as a Researcher in Intellectual Property and Commercialization Strategy.

Earlier in their career, Katherine held positions as Director of Intellectual Property at the Beaulieu-Saucier Pharmacogenomics Centre and Director of Advocacy and Promotion at the Centre of Excellence in Personalized Medicine. In these roles, they managed IP portfolios, aligned research efforts with IP and clinical development strategies, and led outreach and partnership development initiatives.

Katherine's career in the biopharmaceutical industry began at Caprion Pharmaceuticals, where they worked as an Associate in IP from 1999 to 2006. Katherine later joined Ambrilia Biopharma Inc. as the Director of Intellectual Property from 2006 to 2011.

Overall, Katherine Bonter has a strong background in IP strategy, commercialization, and rare disease clinical development, and has held various leadership positions in both industry and academia.

Katherine Bonter has a comprehensive education history. In 1990, they began their undergraduate studies at Concordia University, where they obtained a Bachelor of Science (B.Sc.) degree in Biochemistry and Chemistry in 1994. Following this, they pursued further studies at the same institution and earned a Master of Science (MSc) degree in Neuroscience and Biochemistry from 1994 to 1997.

In 2003, Katherine enrolled in a Summer Intellectual Property Course at McGill University, focusing on Intellectual Property Law. Katherine then embarked on a career in this field and, in 2006, attended the Intellectual Property Institute of Canada for a Patent Agent Exam Prep Course, honing their skills in Intellectual Property Law, Patent Drafting, and Prosecution.

Katherine's educational journey culminated in their pursuit of a Doctor of Philosophy (Ph.D.) degree at McGill University from 2015 to 2020, specializing in Innovation Policy.

This chronological summary provides a solid overview of Katherine Bonter's educational background, highlighting their progression from their undergraduate degree to their advanced studies and specialization in the field of Innovation Policy.